ID   PINK1_HUMAN             Reviewed;         581 AA.
AC   Q9BXM7; Q8N6T9; Q8NBU3; Q96DE4;
DT   07-JUN-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2001, sequence version 1.
DT   02-NOV-2010, entry version 91.
DE   RecName: Full=Serine/threonine-protein kinase PINK1, mitochondrial;
DE            EC=2.7.11.1;
DE   AltName: Full=BRPK;
DE   AltName: Full=PTEN-induced putative kinase protein 1;
DE   Flags: Precursor;
GN   Name=PINK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RC   TISSUE=Endometrium;
RX   MEDLINE=21385714; PubMed=11494141; DOI=10.1038/sj.onc.1204608;
RA   Unoki M., Nakamura Y.;
RT   "Growth-suppressive effects of BPOZ and EGR2, two genes involved in
RT   the PTEN signaling pathway.";
RL   Oncogene 20:4457-4465(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND
RP   AUTOPHOSPHORYLATION.
RC   TISSUE=Placenta;
RX   PubMed=14607334; DOI=10.1016/S0304-3835(03)00443-9;
RA   Nakajima A., Kataoka K., Hong M., Sakaguchi M., Huh N.-H.;
RT   "BRPK, a novel protein kinase showing increased expression in mouse
RT   cancer cell lines with higher metastatic potential.";
RL   Cancer Lett. 201:195-201(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANTS
RP   THR-340 AND THR-521.
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Leukocyte, and Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   SUBCELLULAR LOCATION, AND MEMBRANE TOPOLOGY.
RX   PubMed=18687899; DOI=10.1073/pnas.0802814105;
RA   Zhou C., Huang Y., Shao Y., May J., Prou D., Perier C., Dauer W.,
RA   Schon E.A., Przedborski S.;
RT   "The kinase domain of mitochondrial PINK1 faces the cytoplasm.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:12022-12027(2008).
RN   [7]
RP   VARIANTS PARK6 PHE-92; PRO-168 AND HIS-464, AND VARIANTS LEU-296;
RP   THR-340; THR-442; LYS-476; THR-521 AND ASN-525.
RX   PubMed=15349860; DOI=10.1002/ana.20256;
RA   Valente E.M., Salvi S., Ialongo T., Marongiu R., Elia A.E., Caputo V.,
RA   Romito L., Albanese A., Dallapiccola B., Bentivoglio A.R.;
RT   "PINK1 mutations are associated with sporadic early-onset
RT   parkinsonism.";
RL   Ann. Neurol. 56:336-341(2004).
RN   [8]
RP   VARIANTS PARK6 GLN-271; PRO-347 AND GLY-417.
RX   PubMed=15349870; DOI=10.1002/ana.20251;
RA   Hatano Y., Li Y., Sato K., Asakawa S., Yamamura Y., Tomiyama H.,
RA   Yoshino H., Asahina M., Kobayashi S., Hassin-Baer S., Lu C.-S.,
RA   Ng A.R., Rosales R.L., Shimizu N., Toda T., Mizuno Y., Hattori N.;
RT   "Novel PINK1 mutations in early-onset parkinsonism.";
RL   Ann. Neurol. 56:424-427(2004).
RN   [9]
RP   ERRATUM.
RA   Hatano Y., Li Y., Sato K., Asakawa S., Yamamura Y., Tomiyama H.,
RA   Yoshino H., Asahina M., Kobayashi S., Hassin-Baer S., Lu C.-S.,
RA   Ng A.R., Rosales R.L., Shimizu N., Toda T., Mizuno Y., Hattori N.;
RL   Ann. Neurol. 56:603-603(2004).
RN   [10]
RP   VARIANTS PARK6 LYS-240; PRO-347 AND PRO-489, AND VARIANTS GLY-231;
RP   ILE-235; GLY-263; LEU-318; THR-339; THR-340; HIS-362; SER-425; LYS-476
RP   AND THR-521.
RX   PubMed=15596610; DOI=10.1001/archneur.61.12.1898;
RA   Rogaeva E., Johnson J., Lang A.E., Gulick C., Gwinn-Hardy K.,
RA   Kawarai T., Sato C., Morgan A., Werner J., Nussbaum R., Petit A.,
RA   Okun M.S., McInerney A., Mandel R., Groen J.L., Fernandez H.H.,
RA   Postuma R., Foote K.D., Salehi-Rad S., Liang Y., Reimsnider S.,
RA   Tandon A., Hardy J., St George-Hyslop P., Singleton A.B.;
RT   "Analysis of the PINK1 gene in a large cohort of cases with Parkinson
RT   disease.";
RL   Arch. Neurol. 61:1898-1904(2004).
RN   [11]
RP   VARIANT PARK6 HIS-147.
RX   PubMed=15505171;
RA   Healy D.G., Abou-Sleiman P.M., Gibson J.M., Ross O.A., Jain S.,
RA   Gandhi S., Gosal D., Muqit M.M.K., Wood N.W., Lynch T.;
RT   "PINK1 (PARK6) associated Parkinson disease in Ireland.";
RL   Neurology 63:1486-1488(2004).
RN   [12]
RP   VARIANT PARK6 ASP-309, CHARACTERIZATION OF VARIANT PARK6 ASP-309,
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=15087508; DOI=10.1126/science.1096284;
RA   Valente E.M., Abou-Sleiman P.M., Caputo V., Muqit M.M.K., Harvey K.,
RA   Gispert S., Ali Z., Del Turco D., Bentivoglio A.R., Healy D.G.,
RA   Albanese A., Nussbaum R., Gonzalez-Maldonado R., Deller T., Salvi S.,
RA   Cortelli P., Gilks W.P., Latchman D.S., Harvey R.J., Dallapiccola B.,
RA   Auburger G., Wood N.W.;
RT   "Hereditary early-onset Parkinson's disease caused by mutations in
RT   PINK1.";
RL   Science 304:1158-1160(2004).
RN   [13]
RP   VARIANT PARK6 VAL-268.
RX   PubMed=16207217; DOI=10.1111/j.1399-0004.2005.00500.x;
RA   Tan E.K., Yew K., Chua E., Shen H., Jamora R.D., Lee E., Puong K.Y.,
RA   Zhao Y., Pavanni R., Wong M.C., Puvan K., Yih Y., Tan L.C.S.;
RT   "Analysis of PINK1 in Asian patients with familial parkinsonism.";
RL   Clin. Genet. 68:468-470(2005).
RN   [14]
RP   VARIANTS PARK6 HIS-279 AND GLN-534 INS, AND VARIANT LEU-115.
RX   PubMed=15970950; DOI=10.1038/sj.ejhg.5201455;
RA   Klein C., Djarmati A., Hedrich K., Schaefer N., Scaglione C.,
RA   Marchese R., Kock N., Schuele B., Hiller A., Lohnau T., Winkler S.,
RA   Wiegers K., Hering R., Bauer P., Riess O., Abbruzzese G.,
RA   Martinelli P., Pramstaller P.P.;
RT   "PINK1, Parkin, and DJ-1 mutations in Italian patients with early-
RT   onset parkinsonism.";
RL   Eur. J. Hum. Genet. 13:1086-1093(2005).
RN   [15]
RP   CHARACTERIZATION OF VARIANTS PARK6 PRO-168 AND ASP-309.
RX   PubMed=16207731; DOI=10.1093/hmg/ddi377;
RA   Silvestri L., Caputo V., Bellacchio E., Atorino L., Dallapiccola B.,
RA   Valente E.M., Casari G.;
RT   "Mitochondrial import and enzymatic activity of PINK1 mutants
RT   associated to recessive parkinsonism.";
RL   Hum. Mol. Genet. 14:3477-3492(2005).
RN   [16]
RP   VARIANT PARK6 ARG-388.
RX   PubMed=15955953; DOI=10.1212/01.WNL.0000164009.36740.4E;
RA   Li Y., Tomiyama H., Sato K., Hatano Y., Yoshino H., Atsumi M.,
RA   Kitaguchi M., Sasaki S., Kawaguchi S., Miyajima H., Toda T.,
RA   Mizuno Y., Hattori N.;
RT   "Clinicogenetic study of PINK1 mutations in autosomal recessive early-
RT   onset parkinsonism.";
RL   Neurology 64:1955-1957(2005).
RN   [17]
RP   VARIANTS PARK6 PRO-168 AND LEU-196, AND VARIANTS LEU-115; THR-340;
RP   LYS-476 AND THR-521.
RX   PubMed=16009891; DOI=10.1212/01.wnl.0000167546.39375.82;
RG   The Italian Parkinson genetics network;
RA   Bonifati V., Rohe C.F., Breedveld G.J., Fabrizio E., De Mari M.,
RA   Tassorelli C., Tavella A., Marconi R., Nicholl D.J., Chien H.F.,
RA   Fincati E., Abbruzzese G., Marini P., De Gaetano A., Horstink M.W.,
RA   Maat-Kievit J.A., Sampaio C., Antonini A., Stocchi F., Montagna P.,
RA   Toni V., Guidi M., Dalla Libera A., Tinazzi M., De Pandis F.,
RA   Fabbrini G., Goldwurm S., de Klein A., Barbosa E., Lopiano L.,
RA   Martignoni E., Lamberti P., Vanacore N., Meco G., Oostra B.A.;
RT   "Early-onset parkinsonism associated with PINK1 mutations: frequency,
RT   genotypes, and phenotypes.";
RL   Neurology 65:87-95(2005).
RN   [18]
RP   VARIANTS ILE-317; THR-339; THR-383; SER-411; HIS-431; SER-451;
RP   SER-461; LYS-476; PRO-501 AND ARG-575, AND CHARACTERIZATION OF
RP   VARIANTS HIS-431; SER-451; LYS-476; PRO-501 AND ARG-575.
RX   PubMed=16969854; DOI=10.1002/ana.20960;
RA   Abou-Sleiman P.M., Muqit M.M.K., McDonald N.Q., Yang Y.X., Gandhi S.,
RA   Healy D.G., Harvey K., Harvey R.J., Deas E., Bhatia K., Quinn N.,
RA   Lees A., Latchman D.S., Wood N.W.;
RT   "A heterozygous effect for PINK1 mutations in Parkinson's disease?";
RL   Ann. Neurol. 60:414-419(2006).
RN   [19]
RP   VARIANT PARK6 ASP-217.
RX   PubMed=16966503; DOI=10.1001/archneur.63.9.1257;
RA   Leutenegger A.-L., Salih M.A.M., Ibanez P., Mukhtar M.M., Lesage S.,
RA   Arabi A., Lohmann E., Duerr A., Ahmed A.E.M., Brice A.;
RT   "Juvenile-onset Parkinsonism as a result of the first mutation in the
RT   adenosine triphosphate orientation domain of PINK1.";
RL   Arch. Neurol. 63:1257-1261(2006).
RN   [20]
RP   VARIANT PARK6 MET-313.
RX   PubMed=17030667; DOI=10.1001/archneur.63.10.1483;
RA   Chishti M.A., Bohlega S., Ahmed M., Loualich A., Carroll P., Sato C.,
RA   St George-Hyslop P., Westaway D., Rogaeva E.;
RT   "T313M PINK1 mutation in an extended highly consanguineous Saudi
RT   family with early-onset Parkinson disease.";
RL   Arch. Neurol. 63:1483-1485(2006).
RN   [21]
RP   VARIANTS PARK6 GLY-125; LYS-240; PRO-369; ALA-386 AND VAL-409.
RX   PubMed=16401616; DOI=10.1093/brain/awl005;
RG   The French Parkinson's disease genetics study group;
RA   Ibanez P., Lesage S., Lohmann E., Thobois S., De Michele G., Borg M.,
RA   Agid Y., Durr A., Brice A.;
RT   "Mutational analysis of the PINK1 gene in early-onset parkinsonism in
RT   Europe and North Africa.";
RL   Brain 129:686-694(2006).
RN   [22]
RP   VARIANT PARK6 LEU-399.
RX   PubMed=16632486; DOI=10.1093/hmg/ddl104;
RA   Tang B., Xiong H., Sun P., Zhang Y., Wang D., Hu Z., Zhu Z., Ma H.,
RA   Pan Q., Xia J.-H., Xia K., Zhang Z.;
RT   "Association of PINK1 and DJ-1 confers digenic inheritance of early-
RT   onset Parkinson's disease.";
RL   Hum. Mol. Genet. 15:1816-1825(2006).
RN   [23]
RP   VARIANT PARK6 THR-280, AND VARIANTS THR-340 AND THR-521.
RX   PubMed=16482571; DOI=10.1002/mds.20810;
RA   Tan E.-K., Yew K., Chua E., Puvan K., Shen H., Lee E., Puong K.-Y.,
RA   Zhao Y., Pavanni R., Wong M.-C., Jamora D., de Silva D., Moe K.-T.,
RA   Woon F.-P., Yuen Y., Tan L.;
RT   "PINK1 mutations in sporadic early-onset Parkinson's disease.";
RL   Mov. Disord. 21:789-793(2006).
RN   [24]
RP   VARIANT PARK6 GLN-407, AND VARIANTS THR-340 AND THR-521.
RX   PubMed=16257123; DOI=10.1016/j.neulet.2005.10.005;
RA   Fung H.-C., Chen C.-M., Hardy J., Singleton A.B., Lee-Chen G.-J.,
RA   Wu Y.-R.;
RT   "Analysis of the PINK1 gene in a cohort of patients with sporadic
RT   early-onset parkinsonism in Taiwan.";
RL   Neurosci. Lett. 394:33-36(2006).
RN   [25]
RP   VARIANTS [LARGE SCALE ANALYSIS] TRP-148; SER-196; LEU-209; LEU-215;
RP   THR-339; THR-340; ILE-341; PHE-377; THR-477 AND THR-521.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [26]
RP   VARIANTS PHE-67; PRO-68; TRP-98; SER-111; VAL-124; MET-145; ASN-186;
RP   ILE-257 VAL-268; GLN-276; LEU-296; ILE-317; LEU-322; THR-339; THR-383;
RP   VAL-395; THR-442; LYS-476; ASN-525 AND THR-537.
RX   PubMed=18330912; DOI=10.1002/humu.20719;
RG   The Italian PD study group;
RA   Marongiu R., Ferraris A., Ialongo T., Michiorri S., Soleti F.,
RA   Ferrari F., Elia A.E., Ghezzi D., Albanese A., Altavista M.C.,
RA   Antonini A., Barone P., Brusa L., Cortelli P., Martinelli P.,
RA   Pellecchia M.T., Pezzoli G., Scaglione C., Stanzione P., Tinazzi M.,
RA   Zecchinelli A., Zeviani M., Cassetta E., Garavaglia B.,
RA   Dallapiccola B., Bentivoglio A.R., Valente E.M.;
RT   "PINK1 heterozygous rare variants: prevalence, significance and
RT   phenotypic spectrum.";
RL   Hum. Mutat. 29:565-565(2008).
CC   -!- FUNCTION: Protects against mitochondrial dysfunction during
CC       cellular stress, potentially by phosphorylating mitochondrial
CC       proteins.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR: Magnesium.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion outer membrane; Single-pass
CC       membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9BXM7-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9BXM7-2; Sequence=VSP_050754, VSP_050755;
CC         Note=No experimental confirmation available;
CC   -!- TISSUE SPECIFICITY: Highly expressed in heart, skeletal muscle and
CC       testis, and at lower levels in brain, placenta, liver, kidney,
CC       pancreas, prostate, ovary and small intestine. Present in the
CC       embryonic testis from an early stage of development.
CC   -!- PTM: Autophosphorylated.
CC   -!- DISEASE: Defects in PINK1 are the cause of Parkinson disease type
CC       6 (PARK6) [MIM:605909]. A neurodegenerative disorder characterized
CC       by parkinsonian signs such as rigidity, resting tremor and
CC       bradykinesia. A subset of patients manifest additional symptoms
CC       including hyperreflexia, autonomic instability, dementia and
CC       psychiatric disturbances. Symptoms show diurnal fluctuation and
CC       can improve after sleep.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr
CC       protein kinase family.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/PINK1";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB053323; BAB55647.1; -; mRNA.
DR   EMBL; AF316873; AAK28062.1; -; mRNA.
DR   EMBL; AK075225; BAC11484.1; -; mRNA.
DR   EMBL; AL391357; CAH73475.1; -; Genomic_DNA.
DR   EMBL; BC009534; AAH09534.1; -; mRNA.
DR   EMBL; BC028215; AAH28215.1; -; mRNA.
DR   IPI; IPI00307065; -.
DR   IPI; IPI00411562; -.
DR   RefSeq; NP_115785.1; -.
DR   UniGene; Hs.389171; -.
DR   ProteinModelPortal; Q9BXM7; -.
DR   SMR; Q9BXM7; 151-503, 311-534.
DR   DIP; DIP-29427N; -.
DR   IntAct; Q9BXM7; 2.
DR   STRING; Q9BXM7; -.
DR   PRIDE; Q9BXM7; -.
DR   Ensembl; ENST00000321556; ENSP00000364204; ENSG00000158828.
DR   GeneID; 65018; -.
DR   KEGG; hsa:65018; -.
DR   UCSC; uc001bdm.1; human.
DR   UCSC; uc001bdn.1; human.
DR   CTD; 65018; -.
DR   GeneCards; GC01P020959; -.
DR   H-InvDB; HIX0000218; -.
DR   H-InvDB; HIX0200135; -.
DR   HGNC; HGNC:14581; PINK1.
DR   HPA; CAB026191; -.
DR   HPA; HPA001931; -.
DR   MIM; 168600; phenotype.
DR   MIM; 605909; phenotype.
DR   MIM; 608309; gene.
DR   Orphanet; 2828; Genetic Parkinson disease.
DR   PharmGKB; PA33325; -.
DR   eggNOG; prNOG04091; -.
DR   HOGENOM; HBG716083; -.
DR   HOVERGEN; HBG053601; -.
DR   InParanoid; Q9BXM7; -.
DR   OMA; WNISAGS; -.
DR   OrthoDB; EOG9TXFCH; -.
DR   PhylomeDB; Q9BXM7; -.
DR   BRENDA; 2.7.11.1; 247.
DR   NextBio; 67218; -.
DR   ArrayExpress; Q9BXM7; -.
DR   Bgee; Q9BXM7; -.
DR   CleanEx; HS_PINK1; -.
DR   Genevestigator; Q9BXM7; -.
DR   GermOnline; ENSG00000158828; Homo sapiens.
DR   GO; GO:0005829; C:cytosol; IDA:BHF-UCL.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005741; C:mitochondrial outer membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0055131; F:C3HC4-type RING finger domain binding; IPI:BHF-UCL.
DR   GO; GO:0010857; F:calcium-dependent protein kinase activity; IDA:BHF-UCL.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0008219; P:cell death; IEA:UniProtKB-KW.
DR   GO; GO:0007243; P:intracellular protein kinase cascade; IDA:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-k...; IDA:BHF-UCL.
DR   GO; GO:0090200; P:positive regulation of release of cytochrom...; IMP:BHF-UCL.
DR   GO; GO:0043254; P:regulation of protein complex assembly; IDA:BHF-UCL.
DR   GO; GO:0031396; P:regulation of protein ubiquitination; IDA:BHF-UCL.
DR   GO; GO:0006950; P:response to stress; IDA:UniProtKB.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017442; Se/Thr_prot_kinase-like_dom.
DR   InterPro; IPR008271; Ser/Thr_prot_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; FALSE_NEG.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Complete proteome;
KW   Disease mutation; Kinase; Magnesium; Membrane; Metal-binding;
KW   Mitochondrion; Mitochondrion outer membrane; Neurodegeneration;
KW   Nucleotide-binding; Parkinsonism; Phosphoprotein; Polymorphism;
KW   Serine/threonine-protein kinase; Transferase; Transit peptide;
KW   Transmembrane; Transmembrane helix.
FT   TRANSIT       1     77       Mitochondrion (Potential).
FT   CHAIN        78    581       Serine/threonine-protein kinase PINK1,
FT                                mitochondrial.
FT                                /FTId=PRO_0000024369.
FT   TOPO_DOM     78     93       Mitochondrial intermembrane (Potential).
FT   TRANSMEM     94    110       Helical; (Potential).
FT   TOPO_DOM    111    581       Cytoplasmic (Potential).
FT   DOMAIN      156    511       Protein kinase.
FT   NP_BIND     162    170       ATP (By similarity).
FT   ACT_SITE    362    362       Proton acceptor (By similarity).
FT   BINDING     186    186       ATP (By similarity).
FT   VAR_SEQ       1    307       Missing (in isoform 2).
FT                                /FTId=VSP_050754.
FT   VAR_SEQ     308    320       LGHGRTLFLVMKN -> MCGSQRPSPLSTS (in
FT                                isoform 2).
FT                                /FTId=VSP_050755.
FT   VARIANT      67     67       L -> F.
FT                                /FTId=VAR_046566.
FT   VARIANT      68     68       R -> P.
FT                                /FTId=VAR_046567.
FT   VARIANT      92     92       C -> F (in PARK6).
FT                                /FTId=VAR_046568.
FT   VARIANT      98     98       R -> W.
FT                                /FTId=VAR_046569.
FT   VARIANT     111    111       I -> S.
FT                                /FTId=VAR_046570.
FT   VARIANT     115    115       Q -> L.
FT                                /FTId=VAR_046571.
FT   VARIANT     124    124       A -> V.
FT                                /FTId=VAR_046572.
FT   VARIANT     125    125       C -> G (in PARK6).
FT                                /FTId=VAR_062773.
FT   VARIANT     145    145       T -> M (in dbSNP:rs45604240).
FT                                /FTId=VAR_046573.
FT   VARIANT     147    147       R -> H (in PARK6; uncertain
FT                                pathogenicity).
FT                                /FTId=VAR_046574.
FT   VARIANT     148    148       L -> W (in dbSNP:rs56297806).
FT                                /FTId=VAR_041010.
FT   VARIANT     168    168       A -> P (in PARK6; has reduced
FT                                autophosphorylation activity compared to
FT                                wild-type; localizes to the mitochondria
FT                                and immunogold experiments reveal that
FT                                both wild-type and mutant proteins face
FT                                the mitochondrial intermembrane space).
FT                                /FTId=VAR_046575.
FT   VARIANT     186    186       K -> N.
FT                                /FTId=VAR_046576.
FT   VARIANT     196    196       P -> L (in PARK6).
FT                                /FTId=VAR_046577.
FT   VARIANT     196    196       P -> S (in dbSNP:rs35802484).
FT                                /FTId=VAR_041011.
FT   VARIANT     209    209       P -> L (in dbSNP:rs34677717).
FT                                /FTId=VAR_041012.
FT   VARIANT     215    215       P -> L (in a glioblastoma multiforme
FT                                sample; somatic mutation).
FT                                /FTId=VAR_041013.
FT   VARIANT     217    217       A -> D (in PARK6).
FT                                /FTId=VAR_046578.
FT   VARIANT     231    231       E -> G.
FT                                /FTId=VAR_046579.
FT   VARIANT     235    235       N -> I.
FT                                /FTId=VAR_046580.
FT   VARIANT     240    240       E -> K (in PARK6).
FT                                /FTId=VAR_046581.
FT   VARIANT     257    257       T -> I.
FT                                /FTId=VAR_046582.
FT   VARIANT     263    263       R -> G.
FT                                /FTId=VAR_046583.
FT   VARIANT     268    268       L -> V (in PARK6).
FT                                /FTId=VAR_046584.
FT   VARIANT     271    271       H -> Q (in PARK6).
FT                                /FTId=VAR_046585.
FT   VARIANT     276    276       R -> Q.
FT                                /FTId=VAR_046586.
FT   VARIANT     279    279       R -> H (in PARK6).
FT                                /FTId=VAR_046587.
FT   VARIANT     280    280       A -> T (in PARK6; early-onset).
FT                                /FTId=VAR_062774.
FT   VARIANT     296    296       P -> L.
FT                                /FTId=VAR_046588.
FT   VARIANT     305    305       P -> L (in dbSNP:rs7349186).
FT                                /FTId=VAR_018993.
FT   VARIANT     309    309       G -> D (in PARK6; fails to maintain
FT                                mitochondrial membrane potential and
FT                                protect against apoptosis following
FT                                induction of stress; has reduced
FT                                autophosphorylation activity compared to
FT                                wild-type; localizes to the mitochondria
FT                                and immunogold experiments reveal that
FT                                both wild-type and mutant proteins face
FT                                the mitochondrial intermembrane space).
FT                                /FTId=VAR_018994.
FT   VARIANT     313    313       T -> M (in PARK6).
FT                                /FTId=VAR_046589.
FT   VARIANT     317    317       V -> I.
FT                                /FTId=VAR_046590.
FT   VARIANT     318    318       M -> L.
FT                                /FTId=VAR_046591.
FT   VARIANT     322    322       P -> L.
FT                                /FTId=VAR_046592.
FT   VARIANT     339    339       A -> T (in dbSNP:rs55831733).
FT                                /FTId=VAR_041014.
FT   VARIANT     340    340       A -> T (in dbSNP:rs3738136).
FT                                /FTId=VAR_018995.
FT   VARIANT     341    341       M -> I (in dbSNP:rs35813094).
FT                                /FTId=VAR_041015.
FT   VARIANT     347    347       L -> P (in PARK6).
FT                                /FTId=VAR_046593.
FT   VARIANT     362    362       D -> H.
FT                                /FTId=VAR_046594.
FT   VARIANT     369    369       L -> P (in PARK6).
FT                                /FTId=VAR_062775.
FT   VARIANT     377    377       C -> F (in dbSNP:rs34203620).
FT                                /FTId=VAR_041016.
FT   VARIANT     383    383       A -> T (in dbSNP:rs45515602).
FT                                /FTId=VAR_046595.
FT   VARIANT     386    386       G -> A (in PARK6).
FT                                /FTId=VAR_062776.
FT   VARIANT     388    388       C -> R (in PARK6).
FT                                /FTId=VAR_046596.
FT   VARIANT     395    395       G -> V.
FT                                /FTId=VAR_046597.
FT   VARIANT     399    399       P -> L (in PARK6; digenic inheritance;
FT                                associated with Ser-39 mutation in PARK7
FT                                gene).
FT                                /FTId=VAR_062777.
FT   VARIANT     407    407       R -> Q (in PARK6; early-onset).
FT                                /FTId=VAR_062778.
FT   VARIANT     409    409       G -> V (in PARK6).
FT                                /FTId=VAR_062779.
FT   VARIANT     411    411       G -> S (in dbSNP:rs45478900).
FT                                /FTId=VAR_046598.
FT   VARIANT     417    417       E -> G (in PARK6).
FT                                /FTId=VAR_046599.
FT   VARIANT     425    425       P -> S.
FT                                /FTId=VAR_046600.
FT   VARIANT     431    431       Y -> H (may predispose to Parkinson
FT                                disease development; shows decreased
FT                                mitochondrial membrane potential under
FT                                stress conditions).
FT                                /FTId=VAR_046601.
FT   VARIANT     442    442       I -> T.
FT                                /FTId=VAR_046602.
FT   VARIANT     451    451       N -> S (may predispose to Parkinson
FT                                disease development; shows decreased
FT                                mitochondrial membrane potential under
FT                                stress conditions).
FT                                /FTId=VAR_046603.
FT   VARIANT     461    461       L -> S.
FT                                /FTId=VAR_046604.
FT   VARIANT     464    464       R -> H (in PARK6).
FT                                /FTId=VAR_046605.
FT   VARIANT     476    476       E -> K (may predispose to Parkinson
FT                                disease development; shows decreased
FT                                mitochondrial membrane potential under
FT                                stress conditions).
FT                                /FTId=VAR_046606.
FT   VARIANT     477    477       S -> T (in dbSNP:rs34416410).
FT                                /FTId=VAR_041017.
FT   VARIANT     489    489       L -> P (in PARK6).
FT                                /FTId=VAR_046607.
FT   VARIANT     501    501       R -> P (may predispose to Parkinson
FT                                disease development; shows decreased
FT                                mitochondrial membrane potential under
FT                                stress conditions).
FT                                /FTId=VAR_046608.
FT   VARIANT     521    521       N -> T (in dbSNP:rs1043424).
FT                                /FTId=VAR_018996.
FT   VARIANT     525    525       D -> N.
FT                                /FTId=VAR_046609.
FT   VARIANT     534    534       Q -> QQ (in PARK6).
FT                                /FTId=VAR_046610.
FT   VARIANT     537    537       A -> T.
FT                                /FTId=VAR_046611.
FT   VARIANT     575    575       C -> R (may predispose to Parkinson
FT                                disease development; shows decreased
FT                                mitochondrial membrane potential under
FT                                stress conditions).
FT                                /FTId=VAR_046612.
FT   CONFLICT    209    209       P -> A (in Ref. 5; AAH28215).
FT   CONFLICT    419    419       S -> P (in Ref. 3; BAC11484).
SQ   SEQUENCE   581 AA;  62769 MW;  721FE01F63263A64 CRC64;
     MAVRQALGRG LQLGRALLLR FTGKPGRAYG LGRPGPAAGC VRGERPGWAA GPGAEPRRVG
     LGLPNRLRFF RQSVAGLAAR LQRQFVVRAW GCAGPCGRAV FLAFGLGLGL IEEKQAESRR
     AVSACQEIQA IFTQKSKPGP DPLDTRRLQG FRLEEYLIGQ SIGKGCSAAV YEATMPTLPQ
     NLEVTKSTGL LPGRGPGTSA PGEGQERAPG APAFPLAIKM MWNISAGSSS EAILNTMSQE
     LVPASRVALA GEYGAVTYRK SKRGPKQLAP HPNIIRVLRA FTSSVPLLPG ALVDYPDVLP
     SRLHPEGLGH GRTLFLVMKN YPCTLRQYLC VNTPSPRLAA MMLLQLLEGV DHLVQQGIAH
     RDLKSDNILV ELDPDGCPWL VIADFGCCLA DESIGLQLPF SSWYVDRGGN GCLMAPEVST
     ARPGPRAVID YSKADAWAVG AIAYEIFGLV NPFYGQGKAH LESRSYQEAQ LPALPESVPP
     DVRQLVRALL QREASKRPSA RVAANVLHLS LWGEHILALK NLKLDKMVGW LLQQSAATLL
     ANRLTEKCCV ETKMKMLFLA NLECETLCQA ALLLCSWRAA L
//
